Introduction {#s1}
============

microRNAs are one of the first identified classes of non-coding RNAs that can modulate the expression of mRNA-coding transcripts by binding to complementary regions in a target gene's sequence and repressing its expression. Thus, expression levels and availability of these microRNAs can influence gene expression, and there is growing evidence that misregulation of microRNAs is correlated with some forms of cancer ([@bib19]). Naturally occurring microRNA \'sponges\' have been shown to be effective in regulating gene expression by altering the levels of their cognate microRNAs ([@bib5]; [@bib12]). Poliseno and colleagues proposed that pseudogenes, long non-coding RNAs with strong homology to coding sequences, could act as the modulators of gene expression as microRNA sponges ([@bib16]). They demonstrated that the pseudogene *PTENP1* could regulate the expression levels of *PTEN* via their cognate microRNAs miR-19b and miR-20a ([@bib16]).

In this study, Tay and colleagues expanded upon the previous work to propose a unifying hypothesis of regulatory networks composed of competing endogenous RNAs (ceRNAs) ([@bib12]; [@bib19]; [@bib15]). They suggest that protein-coding RNAs, not just non-coding RNAs, can cross-regulate each other based on competition for shared microRNA regulators; ceRNAs can titrate microRNAs from their target genes ([@bib23]). Continuing their focus on the regulation of *PTEN*, one of the most frequently mutated genes in cancer ([@bib20]), Tay and colleagues propose a computational model to identify ceRNAs de novo, termed MuTaME. Using MuTaME, they identified potential ceRNA regulators of *PTEN*, and validated if these candidate ceRNAs could modulate *PTEN* expression in a microRNA-dependent manner ([@bib23]).

In Figure 3C, Tay and colleagues examine if silencing ceRNAs targeting *PTEN* would affect the expression levels of a luciferase construct carrying the 3'UTR of *PTEN*. They co-transfected DU145 cells with siRNAs against the candidate *PTEN* ceRNAs along with a luciferase-*PTEN 3'UTR* construct and measured luciferase activity. After confirming knockdown of each target ceRNA (Supplemental Figure 3A), they reported that the loss of three of their candidate ceRNAs - *SERINC1, VAPA* and *CNOT6L*, but not *ZNF460* - reduced the luciferase activity of the *PTEN 3'UTR* construct. This experiment will be replicated in Protocol 1.

In Figure 3D, they demonstrated that only the 3'UTRs of the candidate ceRNAs were required to affect changes in the luciferase activity of the *PTEN* 3'UTR construct. Ectopic overexpression of the 3'UTRs of the three candidate ceRNAs relieved inhibition of the *PTEN* 3'UTR, as evidenced by increased luciferase activity as compared to controls. This experiment will be replicated in Protocol 2.

To test if this effect was dependent on microRNAs, Tay and colleagues repeated these experiments in *DICER1* mutant HCT116 cells, in which the machinery required for microRNA function is abrogated. Transfection of wild type HCT116 cells with siRNAs targeting the candidate ceRNAs showed a marked reduction in PTEN protein levels, an effect that was not seen in the *DICER1* mutant HCT116 cells (Figures 3G and H). Knockdown of the candidate ceRNAs was confirmed by RT-PCR (Supplemental Figure 3B). This experiment will be replicated in Protocol 3.

PTEN negatively regulates the PI3K/AKT pathway ([@bib21]), so Tay and colleagues examined if ceRNA modulation affected the phosphorylation of AKT. Loss of *CNOT6L* and *VAPA* in DU145 cells elevated pAKT levels after serum stimulation, an effect that was also observed in wild-type HCT116 cells (Figure 5A). However, this effect was abrogated in *DICER1* mutant HCT116 cells (Figure 5A). They also examined the effect of ceRNAs on the tumorigenic properties conferred by loss of PTEN. Silencing of the ceRNAs *CNOT6L* and *VAPA* increased cell proliferation of DU145 cells and wild-type HCT116 cells, similar to silencing of *PTEN* directly (Figure 5B). This effect was less pronounced in *DICER1* mutant HCT116 cells (Figure 5B). These experiments will be replicated in Protocol 4 and 5.

Two papers published simultaneously provide support for the actions of ceRNA regulatory networks. Karreth and colleagues, from the same lab as Tay and colleagues, demonstrated in vivo evidence for the actions of ceRNA regulation using the sleeping beauty transposase system in a mouse model of melanoma to identify and confirm putative *PTEN* ceRNAs ([@bib13]). Karreth and colleagues identified *CNOT6L* as a putative *PTEN* ceRNA through the sleeping beauty transposase system, providing further evidence that *CNOT6L* is indeed involved in *PTEN* regulation. Karreth and colleagues focused on *ZEB2*; using siRNA silencing, they reported that the loss of *ZEB2* reduced PTEN protein levels, and affected downstream phosphorylation of AKT ([@bib13]). As seen in Tay and colleagues, these effects were dependent on functional microRNA processing; *ZEB2* depletion did not affect PTEN levels in *DICER1* mutant HCT116 cells ([@bib13]). Sumazin and colleagues used a bioinformatics approach to identify post-translational regulation and elucidated over 7,000 genes they proposed acted as miRNA sponges. By comparing the miRNA programs of genes, they could identify genes with common miR programs, indicating the potential for miRNA-mediated crosstalk between those two genes ([@bib22]). They tested their findings by exploring the regulation of *PTEN*, demonstrating that silencing of putative miRNA program-mediated regulators (mPRs) of *PTEN* decreased *PTEN* expression, and, conversely, that the perturbation of PTEN levels could inversely affect the expression of its mPRs. These manipulations also affected tumor cell growth rates, indicating potential in vivo effects of changes to mPR regulatory networks ([@bib22]). Since the publication of these three papers, numerous other examples of ceRNA regulation have been reported in muscle differentiation ([@bib4]), human embryonic stem cell renewal ([@bib24]), regulation of sex determination by SRY ([@bib11]), breast cancer ([@bib25]; [@bib26]; [@bib27]), lymphoma ([@bib14]) and the regulation of the tumor-related HMGA1 ([@bib9]).

The Pandolfi group followed up on their 2011 paper by generating a mathematical model to predict optimal conditions for ceRNA activity, based on a molecular titration mechanism whose effects were correlated to the relative levels of the ceRNA and its target ([@bib1]). They then tested their in silico predictions by experimentally exploring the effect of *VAPA* on *PTEN* expression. While silencing of *VAPA* did decrease *PTEN* expression in all five cell lines tested, they noted that the amount of silencing was correlated with the initial *VAPA:PTEN* expression ratio ([@bib1]). However, Denzler and colleagues challenge the notion that perturbations in ceRNA expression levels could affect target genes at all ([@bib7]). Denzler and colleagues and Ala and colleagues both state that ceRNA effects are dependent on the kinetics of binding, which in turn relies upon the ratio of microRNAs to target sites; increasing the number of target sites through expression of ceRNAs is postulated to affect target gene repression. By quantifying the absolute copy number of the well-studied highly abundant miR-122 and its target sites, Denzler and colleagues showed that large, physiologically unlikely changes in ceRNA expression levels would be required to alter the microRNA: target site ratio enough to perturb target gene expression, casting doubt on the ability of these putative ceRNAs to affect changes in target gene expression levels ([@bib3]; [@bib7]). This view was contradicted by Bosson and colleagues, who identified over 3,000 high affinity target sites they claimed could be affected by ceRNAs due to low endogenous microRNA: target site ratios ([@bib2]). The activity and impact of potential ceRNA networks is an area of active interest (for review, see [@bib6]).

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: Knock-down of ceRNA network genes results in decreased PTEN-3'UTR luciferase expression {#s2-1}
---------------------------------------------------------------------------------------------------

This protocol describes how to silence expression of ceRNA network genes and measure effects on *PTEN* expression by measuring *PTEN* 3'UTR luciferase activity, as seen in Figures 3C and Supplementary S3A.

### Sampling {#s2-1-1}

-   This experiment will include four biological replicates (Luciferase assay) and four biological replicates (qRT-PCR) for a minimum power of 80%.See Power Calculations section for details.

-   Each experiment consists of DU145 cells co-transfected with a luciferase-*PTEN* 3'UTR reporter construct and siRNA against *PTEN* ceRNAs:Cohort 1: siRNA against nontargeting control 2 (siNC)Cohort 2: siGENOME siRNA against *SERINC1* (siSER)Cohort 3: siGENOME siRNA against *ZNF460* (siZNF)Cohort 4: siGENOME siRNA against *VAPA* (siVAPA)Cohort 5: siGENOME siRNA against *CNOT6L* (siCNO)Cohort 6: siGENOME siRNA against *PTEN* (siPTEN)Cohort 7: siGLO RISC-free siRNA (transfection control)

-   Effects of silencing ceRNAs will be tested withLuciferase assay of *PTEN* 3'UTR expression (Figure 3C)qRT-PCR to confirm target gene silencing (Supplementary Fig S3A)siGLO fluorescence to confirm transfection efficiency

### Materials and reagents {#s2-1-2}

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                     Type                   Manufacturer         Catalog \#         Comments
  ------------------------------------------- ---------------------- -------------------- ------------------ ---------------------------------------------
  DU145 human prostate cancer cells           Cells                  ATCC                 HTB-81             

  psiCHECK-2-PTEN 3\'UTR plasmid              Plasmid                Addgene              plasmid \#50936    Communicated by original authors

  siGLO RISC-free siRNA siGLO                 siRNA                  Dharmacon            D-001600-01-05     Catalog \# communicated by original authors

  siGenome siRNA for nontargeting control 2   siRNA                  Dharmacon            D-001210-02-05     Catalog \# communicated by original authors

  siGenome siRNA for *SERINC1*                siRNA                  Dharmacon            M-010725-00-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *ZNF460*                 siRNA                  Dharmacon            M-032012-01-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *VAPA*                   siRNA                  Dharmacon            M-021382-01-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *CNOT6L*                 siRNA                  Dharmacon            M-016411-01-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *PTEN*                   siRNA                  Dharmacon            M-003023-02-0005   Catalog \# communicated\
                                                                                                             by original authors

  Dulbecco\'s Modified Eagle\'s\              Cell Culture Reagent   Invitrogen           10313-039          Catalog \# communicated\
  Medium (DMEM)                                                                                              by original authors

  Fetal Bovine Serum (FBS)                    Cell Culture Reagent   Invitrogen           10438-026          Catalog \# communicated\
                                                                                                             by original authors

  Penicillin/Streptomycin                     Cell Culture Reagent   Life Technologies    15140-163          Communicated by original authors

  Glutamine                                   Cell Culture Reagent   Life Technologies    25030-081          Communicated by original authors

  Lipofectamine 2000                          Transfection Reagent   Life Technologies    11668500           Communicated by original authors

  Trypsin                                     Transfection Reagent   Life Technologies    15400-054          Communicated by original authors

  Dual Luciferase Reporter Assay              Luciferase Assay       Promega              E1960              Catalog \# communicated\
                                                                                                             by original authors

  Lysis Buffer (included with\                Buffer                 Promega              E1960              Original not specified
  Dual-Luciferase Reporter Assay)                                                                            

  GLOMAX 96 Microplate Luminometer            Equipment              Promega              E6501              Replaces Promega E8032\
                                                                                                             (communicated by original authors)

  TRIzol reagent                              qPCR reagent           Life Technologies    15596026           Communicated by original authors

  RNeasy kit                                  qPCR reagent           Qiagen               74104              Communicated by original authors

  High Capacity cDNA Archive kit              qPCR reagent           Life Technologies    4368814            Communicated by original authors

  TaqMan probe *PTEN*                         qPCR probes            Life Technologies    Hs02621230_s1      

  TaqMan probe *CNOT6L*                       qPCR probes            Life Technologies    Hs00375913_m1      

  TaqMan probe *VAPA*                         qPCR probes            Life Technologies    Hs00427749_m1      

  TaqMan probe *SERINC1*                      qPCR probes            Life Technologies    Hs00380375_m1      

  TaqMan probe *ZNF460*                       qPCR probes            Life Technologies    Hs01104252_m1      

  TaqMan control probe *ß-ACTIN*              qPCR probes            Life Technologies    Hs00969077_m1      Communicated by original authors

  TaqMan Fast Advanced Master Mix             qPCR reagent           Life Technologies    4444964            Communicated by original authors

  StepOne Plus Real-Time PCR system           Equipment              Applied Biosystems                      Replaces LightCycler 480 System

  Nanodrop 2000C Spectrometer                 Equipment              Thermo Scientific                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-1-3}

Notes:

-   All cells will be sent for mycoplasma testing and STR profiling.

-   DU145 cells are maintained in DMEM supplemented with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37°C in 5% CO~2~ in a humidified atmosphere.

1.  Co-transfect DU145 cells with *PTEN* 3'UTR and siRNAs:Split DU145 cells into four different cultures.These will be biological replicates.Seed cells at 1.2 x 10^5^ cells per well in 12 well dishes for 24.Seed 13 wells: 6 transfection conditions x 2 wells per condition (for Steps 2 and 3) and 1 transfection condition (siGlo RISC free siRNA transfection control) x 1 well.Prepare separate transfection mixtures for each biological replicate.Add 100 ng of psiCHECK-2+PTEN3'UTR and 100 pmol of siRNA QS to 100 µl of Opti-MEM.Transfect a pair of wells with each of the following:siSERINC1siZNF460siVAPAsiCNOT6LsiPTENnon-targeting control (NC)Transfect a single well with the following:siGLO control siRNAIn a separate tube mix 2 µl of Lipofectamine 2000 with 100 µl of Opti-MEM.Scale the volume according to number of replicates.Incubate for 10 min.Combine the plasmid/siRNA and Lipofectamine mixes with gentle mixing and incubate for an additional 20min.Aliquot 200 µl of the plasmid/siRNA and Lipofectamine transfection mix into appropriate well.Mix gently and incubate at 37˚C.Replace growth medium after 4.After 24-48, count the number of fluorescent cells transfected with siGLO relative to total to confirm \>90% transfection efficiency.If transfection is less than 90%, record efficiency, exclude replicate and omit it from the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.If modification to transfection is needed, record and maintain modified steps for remaining replicates.Incubate for 72 at 37˚C in 5% CO~2~ in a humidified atmosphere

2.  Use one well for each transfection to measure luciferase activity:Wash cells with ice-cold PBS, aspirate and add 100 µl of 1X lysis buffer.Place on an orbital shaker for 10min to dissociate the cell layer.Pipette gently to mix and transfer 20 µl of each lysate into one well of a white-walled 96 well plate.Measure firefly and Renilla luciferase activities with the dual-luciferase reporter system with a luminometer according to the manufacturer's instructions.

3.  Using the other well for each transfection, confirm siRNA target knock-down with qRT-PCR:Extract total RNA using TRIzol reagent according to manufacturer's instructions.Purify samples with RNeasy kit according to manufacturer's instructions.Quality check RNA by measuring A~260/280~ and A~260/230~ absorbance ratios.Total RNA can be frozen here until all biological replicates are performed after which the remaining steps will be conducted at one time.Reverse transcribe 1 µg total RNA using High Capacity cDNA Archive kit according to manufacturer's instructions.Perform qRT-PCR to confirm mRNA expression knockdown. Measure mRNA expression for each siRNA transfection sample with its appropriate target and *ß-ACTIN*, and test each probe separately using RNA from the NC transfection.PTENCNOT6LVAPAZNF460SERINC1*β-ACTIN* \[endogenous control communicated by original author\]Prepare 10 µl real-time PCR reaction in triplicate for each reaction consisting of:5 µl TaqMan mastermix0.5 µl TaqMan probe for the gene of interest4.5 µl cDNA (diluted 10x)Use standard TaqMan cycling protocol:50˚C 2 min95˚C 20 s40 cycles of 95˚C 1 s, 60˚C 20 sNormalize each mRNA expression to *ß-ACTIN* and then normalize each siRNA to siNC for that transcript.

4.  Repeat steps 1-3, 3 additional times

### Deliverables {#s2-1-4}

-   Data to be collected:QC image data confirming transfection efficiency by measuring the number of fluorescent cells transfected with siGLORaw data of Renilla and firefly luciferase measures and a graph of luciferase activity for each cohortQC data for total RNA (A~260/280~ and A~260/230~ absorbance ratios)qRT-PCR data to confirm silencing: raw qPCR data and for each sample and a graph of each target gene normalized with *β-ACTIN* and normalized relative to NC expression

### Confirmatory analysis plan {#s2-1-5}

-   Statistical Analysis of the Replication Data:Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.Luciferase assay: One-way ANOVA of luciferase activity in DU145 cells transfected with siRNA against NC, *SERINC1, ZNF460, VAPA, CNOT6L*, or *PTEN*, with the following Bonferroni-corrected comparisons:Non-coding siRNA vs. each of the ceRNA transfected cells (5 comparisons total).qRT-PCR: Bonferroni corrected one-sample *t*-tests of normalized mRNA expression in DU145 cells transfected with siRNA against *SERINC1, ZNF460, VAPA, CNOT6L*, or *PTEN* compared to a constant (siNC = 1) (5 comparisons total).

-   Meta-analysis of original and replication attempt effect sizes:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper, and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-1-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-1-7}

Extracted RNA integrity will be reported with A~260/280~ and A~260/230~ absorbance ratios, and transfection efficiency will be checked using the siGLO control. qRT-PCR will be performed to confirm the silencing of ceRNA expression. The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded, and the procedure will be maintained for the remaining replicates. All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/oblj1/>).

Protocol 2: Overexpression of PTEN ceRNA 3'UTRs network genes results in upregulation of PTEN3'UTR luciferase activity {#s2-2}
----------------------------------------------------------------------------------------------------------------------

This protocol describes how to measure the effect of ectopic overexpression of PTEN ceRNA 3'UTRs in DU145 cells on Luc-PTEN 3'UTR levels. This protocol replicates Figures 3D.

### Sampling {#s2-2-1}

-   This experiment will include six biological replicates for a minimum power of 88%.See Power calculations for details.

-   Each experiment consists of DU145 cells co-transfected with a luciferase-PTEN 3'UTR reporter construct and:Cohort 1: *SERINC1* 3'UTR (SER 3'U)Cohort 2: *VAPA* 3'UTR1 (VAPA 3'U1)Cohort 3: *VAPA* 3'UTR2 (VAPA 3'U2)Cohort 4: *CNOT6L* 3'UTR1 (CNO 3'U1)Cohort 5: *CNOT6L* 3'UTR2 (CNO 3'U2)Cohort 6: *PTEN* 3'UTR (PTEN 3'U)Cohort 7: Empty vector control

-   Effects of overexpressing ceRNAs will be tested withLuciferase assay of PTEN 3'UTR expression (Figure 3D)

### Materials and reagents {#s2-2-2}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                             Type                   Manufacturer                   Catalog \#        Comments
  ----------------------------------- ---------------------- ------------------------------ ----------------- ---------------------------------------------
  DU145 human prostate cancer cells   Cells                  ATCC                           HTB-81            

  psiCHECK-2-PTEN 3\'UTR plasmid      Plasmid                Addgene                        plasmid \#50936   Communicated by original authors

  psiCHECK-2 empty vector             Plasmid                Promega                        C8021             Catalog \# communicated by original authors

  Dulbecco\'s Modified Eagle\'s\      Cell Culture Reagent   Invitrogen                     10313-039         Catalog \# communicated by original authors
  Medium (DMEM)                                                                                               

  Fetal Bovine Serum (FBS)            Cell Culture Reagent   Invitrogen                     10438-026         Catalog \# communicated by original authors

  Penicillin/Streptomycin             Cell Culture Reagent   Life Technologies              15140-163         Communicated by original authors

  Glutamine                           Cell Culture Reagent   Life Technologies              25030-081         Communicated by original authors

  Lipofectamine 2000                  Transfection Reagent   Life Technologies              11668500          Communicated by original authors

  *SERINC1* 3'UTR vector              Plasmid                Provided by original authors                     

  *VAPA* 3'UTR1 vector                Plasmid                Provided by original authors                     

  *VAPA* 3'UTR2 vector                Plasmid                Provided by original authors                     

  *CNOT6L* 3'UTR1 vector              Plasmid                Provided by original authors                     

  *CNOT6L* 3'UTR2 vector              Plasmid                Provided by original authors                     

  *PTEN* 3'UTR vector                 Plasmid                Provided by original authors                     

  Trypsin                             Transfection Reagent   Life Technologies              15400-054         Communicated by original authors

  Dual Luciferase Reporter Assay      Luciferase Assay       Promega                        E1960             Catalog \# communicated by original authors

  Luminometer                         Equipment              Promega                        E8032             Catalog \# communicated by original authors
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-2-3}

Notes:

-   All cells will be sent for mycoplasma testing and STR profiling.

-   DU145 cells are maintained in DMEM supplemented with 10% FBS, ^\#^100 U/ml penicillin/100 μg/ml streptomycin, and ^\#^2 mM glutamine at 37˚C in 5% CO~2~ in a humidified atmosphere.

1.  Transfect DU145 cells with *PTEN* 3'UTR and ceRNA 3'UTRs:Separate DU145 cells into 6 different cultures.These will be biological replicates.Seed cells at 1.2 x 10^5^ cells per well in 12 well dishes and incubate for 24 hr.Seed 1 well per biological replicate: 7 transfections x 6 replicates.42 wells total seeded.Prepare the transfection mix by adding 100 ng of psiCHECK-2+PTEN3'UTR and 1 µg of 3'UTR plasmid to 100 µl of Opti-MEM.Transfect one well per replicate with each of the following:*SER* 3'U*VAPA* 3'U1*VAPA* 3'U2*CNO* 3'U1*CNO* 3'U2*PTEN* 3'Uempty vector controlIn a separate tube, mix 2 µl of Lipofectamine 2000 with 100 µl of Opti-MEM.Scale the volume of reagents accordingly.Incubate for 10 min.Combine the plasmid and Lipofectamine mixes and incubate for an additional 20 min.Aliquot 200 µl of the plasmid and Lipofectamine transfection mix into each well. Mix gently and incubate at 37˚C in 5% CO~2~ in a humidified atmosphere.Replace growth medium after 4 hr.Incubate for 72 hr.

2.  Measure renilla and firefly luciferase activity as outlined in Protocol 1 Step 2.

### Deliverables {#s2-2-4}

-   Data to be collected:Raw data of Renilla and firefly luciferase measures and a graph of luciferase activity for each cohort.

### Confirmatory analysis plan {#s2-2-5}

-   Statistical Analysis of the Replication Data:Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.One-way ANOVA of luciferase activity in DU145 cells expressing 3'UTRs *SER, VAPA* 3'U1, *VAPA* 3'U2, *CNO* 3'U1, *CNO* 3'U2, *PTEN*, or empty vector control with the following Bonferroni-corrected planned comparisons:Luciferase activity in each 3'UTR transfection vs. the empty vector control (6 comparisons total).

-   Meta-analysis of original and replication attempt effect sizes:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-2-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-2-7}

The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/oblj1/>).

Protocol 3: Knock-down of ceRNA network genes results in decreased PTEN protein that is dependent on microRNA functioning {#s2-3}
-------------------------------------------------------------------------------------------------------------------------

This protocol describes how to test the effects of siRNA-mediated depletion of *SERINC1, VAPA*, or *CNOT6L* expression on PTEN protein expression in wild-type HCT116 colon cancer cells. It also tests whether these effects are dependent on mature microRNA using Dicer mutant (DICER^Ex5^) HCT116 cells. It replicates Figures 3G,H, and Supplementary Figure 3B.

### Sampling {#s2-3-1}

-   The experiment will be repeated four times (Western blot) and three times (qRT-PCR) for a minimum power of 80%.See Power Calculations section for details.

-   Each experiment consists of HCT116 WT and HCT116 DICER^Ex5^ cells transfected with siRNA against PTEN ceRNAs:Cohort 1: siRNA against nontargeting control 2 (siNC)Cohort 2: siGENOME siRNA against *SERINC1* (siSER)Cohort 3: siGENOME siRNA against *VAPA* (siVAPA)Cohort 4: siGENOME siRNA against *CNOT6L* (siCNO)Cohort 5: siGENOME siRNA against *PTEN* (siPTEN)Cohort 6: siGLO RISC-free siRNA (siGLO)

-   Effects of silencing ceRNAs will be tested withWestern Blot for PTEN protein (Figure 3G & 3H)qRT-PCR to confirm target genes were silenced (Supplementary Figure 3B)siGLO fluorescence cell counts to confirm transfection efficiency

### Materials and reagents {#s2-3-2}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                                                                        Type                   Manufacturer                                                                    Catalog \#         Comments
  ------------------------------------------------------------------------------ ---------------------- ------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------
  HCT116 WT and DICER^Ex5^ cells                                                 Cells                  Horizon Discovery                                                               HD R02-019         

  siGLO RISC-free siRNA siGLO                                                    siRNA                  Dharmacon                                                                       D-001600-01-05     

  siGenome siRNA for\                                                            siRNA                  Dharmacon                                                                       D-001210-02-05     Catalog \# communicated\
  nontargeting control 2                                                                                                                                                                                   by original authors

  siGenome siRNA for *SERINC1*                                                   siRNA                  Dharmacon                                                                       M-010725-00-0005   Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  siGenome siRNA for *VAPA*                                                      siRNA                  Dharmacon                                                                       M-021382-01-0005   Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  siGenome siRNA for *CNOT6L*                                                    siRNA                  Dharmacon                                                                       M-016411-01-0005   Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  siGenome siRNA for *PTEN*                                                      siRNA                  Dharmacon                                                                       M-003023-02-0005   Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  Dulbecco\'s Modified Eagle\'s Medium (DMEM)                                    Cell Culture Reagent   Invitrogen                                                                      10313-039          Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  Fetal Bovine Serum (FBS)                                                       Cell Culture Reagent   Invitrogen                                                                      10438-026          Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  Penicillin/Streptomycin                                                        Cell Culture Reagent   Life Technologies                                                               15140-163          Communicated by\
                                                                                                                                                                                                           original authors

  Glutamine                                                                      Cell Culture Reagent   Life Technologies                                                               25030-081          Communicated by\
                                                                                                                                                                                                           original authors

  Trypsin                                                                        Transfection Reagent   Life Technologies                                                               15400-054          Communicated by\
                                                                                                                                                                                                           original authors

  Dharmafect 1                                                                   Transfection Reagent   Thermo Fisher Scientific                                                        T200104            Communicated by\
                                                                                                                                                                                                           original authors

  TRIzol reagent                                                                 qPCR reagent           Life Technologies                                                               15596026           Communicated by\
                                                                                                                                                                                                           original authors

  RNeasy kit                                                                     qPCR reagent           Qiagen                                                                          74104              Communicated by\
                                                                                                                                                                                                           original authors

  High Capacity cDNA Archive kit                                                 qPCR reagent           Life Technologies                                                               4368814            Communicated by\
                                                                                                                                                                                                           original authors

  TaqMan probe *PTEN*                                                            qPCR probes            Life Technologies                                                               Hs02621230_s1      

  TaqMan probe *CNOT6L*                                                          qPCR probes            Life Technologies                                                               Hs00375913_m1      

  TaqMan probe *VAPA*                                                            qPCR probes            Life Technologies                                                               Hs00427749_m1      

  TaqMan probe *SERINC1*                                                         qPCR probes            Life Technologies                                                               Hs00380375_m1      

  TaqMan control probe *ß-ACTIN*                                                 qPCR probes            Life Technologies                                                               Hs00969077_m1      Communicated by\
                                                                                                                                                                                                           original authors

  TaqMan Fast Advanced Master Mix                                                qPCR reagent           Life Technologies                                                               4444964            Communicated by\
                                                                                                                                                                                                           original authors

  StepOne Plus Real-Time PCR system                                              Equipment              Applied Biosystems                                                                                 Replaces LightCycler 480 System

  Nanodrop 2000c Spectrometer                                                    Equipment              Thermo Scientific                                                                                  

  PBS                                                                            Western Reagent        Life Technologies                                                               14190250           Communicated by\
                                                                                                                                                                                                           original authors

  Lysis Buffer                                                                   Western Reagent        RIPA lysis buffer: 50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.5%\                               
                                                                                                        sodium deoxycholate, 0.1% SDS, 5mM EDTA supplemented with protease inhibitors                      

  Protease inhibitors                                                            Western Reagent        Roche Diagnostics                                                               11873580001        Communicated by\
                                                                                                                                                                                                           original authors

  Bradford Assay                                                                 Western Reagent        Bio-Rad                                                                                            Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  Bis-Tris acrylamide NuPAGE gels 4--15% Mini-PROTEAN TGX Precast Protein Gels   Western Reagent        Biorad                                                                          456--1084          Replaces NuPage gels from Life Technologies (communicated by original authors)

  Tris-Glycine SDS PAGE buffer (10x)                                             Western Reagent        National Diagostic                                                              EC-870-4L          Replaces MOPS buffer from Invitrogen

  Nitrocellulose membranes                                                       Western Reagent        Thermo Fisher Scientific                                                        45004006           Catalog \# communicated\
                                                                                                                                                                                                           by original authors

  10xTBS buffer                                                                  Western Reagent        Biorad                                                                          170--6435          Replaces NuPage buffer from Invitrogen

  Methanol                                                                       Reagent                Pharmco                                                                         339000ACSCSGL      Communicated by\
                                                                                                                                                                                                           original authors

  Mouse anti-HSP90 monoclonal\                                                   Antibody               Becton Dickinson                                                                61041              Catalog \# communicated\
  antibody (90kDa)                                                                                                                                                                                         by original authors

  Rabbit anti-PTEN monoclonal\                                                   Antibody               Cell Signaling                                                                  9559               Catalog \# communicated\
  antibody (54kDa)                                                                                                                                                                                         by original authors

  Anti-mouse HRP-conjugated\                                                     Antibody               Abcam                                                                           Ab6728             Original not specified
  secondary antibody                                                                                                                                                                                       

  Amersham ECL Western\                                                          Western Blot Reagent   Amersham                                                                        RPN 2108           Replaces ECL from Applied Biological Materials
  Blotting Detection Kit                                                                                                                                                                                   

  X-ray Film (Hyblot CL, 8x10 inch)                                              Western Blot Reagent   Denville                                                                        E3018              Original not specified

  Spectrophotometer                                                              Equipment              Beckman Coulter                                                                 Spectra max M2     Replaces Beckman Model DU-800 (communicated by original authors)\
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-3-3}

Notes

-   All cells will be sent for mycoplasma testing and STR profiling.

-   HCT116 cells (wild-type and mutant) are maintained in DMEM with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37°C/5% CO~2~ in a humidified atmosphere.

1.  Transfect HCT116 cells with siRNAs:Separate HCT116 WT and DICER ^Ex5^ cells into four different cultures each.These will be biological replicates.For each cell type (WT and DICER Ex5) seed cells at 1.3 x 10^5^ cells per well in 12 well dishesSeed 11 wells per replicate: 5 transfections x 2 wells each (one for Step 2, one for Step 3) and 1 transfection (siGlo) x 1 well.Note: During the last replicate, only seed 6 wells per cell type (5 transfection conditions for Step 2) and 1 transfection condition for siGlo RISC free siRNA transfection control.Transfect cells with 100 nM siRNA (or siGLO controls) using Dharmafect 1 according to manufacturer's instructions.Note: make up a separate transfection mixture for each replicate.Transfect a pair of wells per replicate with each of the following:siNCsiSERsiVAPAsiCNOsiPTENTransfect a single well per replicate with the following:siGLOAfter 24-48 hr, assess number of fluorescent cells transfected with siGLO to confirm \>90% transfection efficiency.If transfection is less than 90%, record efficiency, exclude replicate and omit it from the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.If modification to transfection is needed, record and maintain modified steps for remaining replicates.Incubate for 72 hr at 37˚C in 5% CO~2~ in a humidified atmosphere.Replace growth medium after 4 hr.

2.  Using one of each pair of wells (except during replicate 4), confirm siRNA knock down with qRT-PCR as in Protocol 1 Step 3. Measure mRNA expression for each siRNA transfection sample with its appropriate target and *ß-ACTIN,* and test each probe separately using RNA from the NC control transfection.PTENCNOT6L*VAPA*SERINC1*β-ACTIN* \[endogenous control communicated by original author\]Prepare 10 µl real-time PCR reaction in triplicate for each reaction consisting of:5 µl TaqMan mastermix0.5 µl TaqMan probe for the gene of interest4.5 µl cDNA (diluted 10x)Use standard TaqMan cycling protocol:50˚C 2 min95˚C 20 s40 cycles of 95˚C 1 s, 60˚C 20 sNormalize each mRNA expression to *ß-ACTIN* and then normalize each siRNA to siNC for that transcript.

3.  Using the second well of each pair of wells, assess PTEN protein expression by Western Blot:Wash cells in chilled PBSLyse cells directly in wells by incubating on ice for 20 min with RIPA lysis buffer containing protease inhibitors.Clear lysates by centrifugation at 4°C for 15 min at 12,100*xg*.Determine protein concentrations with Bradford assay following manufacturer's instructions.Separate 5 µg of total protein by SDS-PAGE on 4--15% 4-15% Mini-PROTEAN TGX precast protein gels in Tris-Glycine SDS PAGE buffer.HCT116 cells express high levels of PTEN protein so 5 µg should be sufficient for detection.Transfer to nitrocellulose membranes in transfer buffer containing 10% methanol for 1 hr at 40V at room temperature.\*Confirm protein transfer by Ponceau staining.Block membrane with 5% milk in ^\#^TBST for 30 min.Probe membranes specific primary antibodies:PTEN: 1:1000HSP90: 1:1000Wash membrane 3 times in 1X TBST for 5 min each on shaker.Incubate with ^\#^anti-rabbit (with PTEN primary) or ^\#^anti-mouse (for HSP90 primary) HRP conjugated secondary antibody (1:2000) for 1 hr on shaker at room temperature.Remove membrane from secondary antibody and wash three times in 1X TBST for 5 min each.Prepare ECL solution and incubate membrane.Expose membrane to X-ray film, develop and scan. Take a range of exposures (1 s, 15 s, 60 s) for each film.Note from the original author: Care should be taken not to overload the gel or to overexpose the film. ceRNA regulation may only result in a 50% increase or decrease in protein levels, this difference may be overlooked if the signal is saturated and not within the dynamic range of the film.Normalize PTEN to HSP90 for each sample.

4.  Repeat 3 additional times.

### Deliverables {#s2-3-4}

-   Data to be collected:QC image data confirming transfection efficiency by measuring the number of fluorescent cells transfected with siGLOQC data for total RNA (A~260/280~ and A~260/230~ absorbance ratios)Raw qPCR data for each sample and a graph the mean of each target gene normalized with *β-ACTIN* and normalized relative to NC control. (Compare to Supplementary Figure 3B)Full scans of each western blot with ladder (Compare to Figure 3G)Raw data of band analysis and normalized bands for each sample (Compare to Figure 3H)

### Confirmatory analysis plan {#s2-3-5}

-   Statistical Analysis of the Replication Data:Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.Western blot: Two-way ANOVA of normalized PTEN levels from HCT116 cells (wild type or DICER^Ex5^ cells) transfected with siRNA for SERINC1, VAPA, CNOT6L, PTEN, or control NC followed by Bonferroni-corrected planned comparisons:siNC vs. each siRNA for each cell line (8 comparisons total).qRT-PCR: Bonferroni corrected one-sample *t*-tests of normalized mRNA expression in HCT116 cells (wild type or DICER^Ex5^ cells) transfected with siRNA against *SERINC1, VAPA, CNOT6L*, or *PTEN* compared to a constant (siNC=1) (8 comparisons total).

-   Meta-analysis of original and replication attempt effect sizes:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-3-6}

All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-3-7}

Extracted RNA integrity will be reported with A~260/280~ and A~260/230~ absorbance ratios, and transfection efficiency will be checked using the siGLO control. The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency does not reach \>90%, then any modifications to the transfection protocol will be recorded. qRT-PCR will be performed to confirm silencing of mRNA expression. Images of Ponceau staining to confirm protein transfer. All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/oblj1/>).

Protocol 4: Effect of knock-down of ceRNA network genes on cell proliferation {#s2-4}
-----------------------------------------------------------------------------

This experiment tests the effects of siRNA-mediated depletion of *PTEN, CNOT6L*, and *VAPA* expression on cell proliferation in DU145, HCT116 WT, and HCT116 DICER^Ex5^ cells. It replicates Figure 5B.

### Sampling {#s2-4-1}

-   This experiment will be repeated five (DU145 cells) times and four (HCT116 cells) times for a minimum power of 80%.See Power Calculations section for details.

-   Each experiment consists of DU145, HCT116 WT, and HCT116 DICER^Ex5^ cells transfected with siRNA against PTEN ceRNAs:Cohort 1: siGLO RISC-free siRNA (siGLO)Cohort 2: siRNA against nontargeting control 2 (siNC)Cohort 3: siGENOME siRNA against *VAPA* (siVAPA)Cohort 4: siGENOME siRNA against *CNOT6L* (siCNO)Cohort 5: siGENOME siRNA against *PTEN* (siPTEN)

-   Effects of silencing ceRNAs will be tested withqRT-PCR to confirm target genes were silenced \[additional QC\]siGLO fluorescence cell counts to confirm transfection efficiencyAssessment of cell proliferation (Figure 5B)

### Materials and reagents {#s2-4-2}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                             Type                     Manufacturer               Catalog \#         Comments
  ----------------------------------- ------------------------ -------------------------- ------------------ --------------------------------------------------------------------------
  DU145 human prostate cancer cells   Cells                    ATCC                       HTB-81             

  HCT116 WT and DICER^Ex5^ cells      Cells                    Horizon Discovery          HD R02-019         

  siGLO RISC-free siRNA siGLO         siRNA                    Dharmacon                  D-001600-01-05     

  siGenome siRNA for\                 siRNA                    Dharmacon                  D-001210-02-05     Catalog \# communicated\
  nontargeting control 2                                                                                     by original authors

  siGenome siRNA for *VAPA*           siRNA                    Dharmacon                  M-021382-01-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *CNOT6L*         siRNA                    Dharmacon                  M-016411-01-0005   Catalog \# communicated\
                                                                                                             by original authors

  siGenome siRNA for *PTEN*           siRNA                    Dharmacon                  M-003023-02-0005   Catalog \# communicated\
                                                                                                             by original authors

  Dulbecco\'s Modified Eagle\'s\      Cell Culture Reagent     Invitrogen                 10313-039          Catalog \# communicated\
  Medium (DMEM)                                                                                              by original authors

  Fetal Bovine Serum (FBS)            Cell Culture Reagent     Invitrogen                 10438-026          Catalog \# communicated\
                                                                                                             by original authors

  Penicillin/Streptomycin             Cell Culture Reagent     Life Technologies          15140-163          Communicated by\
                                                                                                             original authors

  Glutamine                           Cell Culture Reagent     Life Technologies          25030-081          Communicated by\
                                                                                                             original authors

  Trypsin                             Transfection Reagent     Life Technologies          15400-054          Communicated by\
                                                                                                             original authors

  Dharmafect 1                        Transfection Reagent     Thermo Fisher Scientific   T200104            Communicated by\
                                                                                                             original authors

  TRIzol reagent                      qPCR reagent             Life Technologies          15596026           Communicated by\
                                                                                                             original authors

  RNeasy kit                          qPCR reagent             Qiagen                     74104              Communicated by\
                                                                                                             original authors

  High Capacity cDNA Archive kit      qPCR reagent             Life Technologies          4368814            Communicated by\
                                                                                                             original authors

  TaqMan probe *PTEN*                 qPCR probes              Life Technologies          Hs02621230_s1      

  TaqMan probe *CNOT6L*               qPCR probes              Life Technologies          Hs00375913_m1      

  TaqMan probe *VAPA*                 qPCR probes              Life Technologies          Hs00427749_m1      

  TaqMan control probe *ß-ACTIN*      qPCR probes              Life Technologies          Hs00969077_m1      Additional control

  TaqMan Fast Advanced Master Mix     qPCR reagent             Life Technologies          4444964            Communicated by original authors

  StepOne Plus Real-Time PCR system   Equipment                Applied Biosystems                            Replaces LightCycler 480 System

  Nanodrop 2000C Spectrometer         Equipment                Thermo Scientific                             

  PBS                                 Western Reagent          Life Technologies          14190250           Communicated by\
                                                                                                             original authors

  Formalin                            Fixative                 Sigma Aldrich              HT501128-4l        Communicated by\
                                                                                                             original authors

  Crystal Violet                      Stain                    Sigma Aldrich              C-3886             Communicated by\
                                                                                                             original authors

  10% acetic acid                     Solubilization reagent   Thermo Fisher Scientific   A38212             Communicated by\
                                                                                                             original authors

  BioTek Synergy HT\                  Equipment                BioTek Instrument                             Replaces Beckman Coulter Model DU-800 (communicated by original authors)
  Multi-mode Microplate Reader                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-4-3}

Notes:

-   HCT116 cells (wild-type and mutant) are maintained in DMEM with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37°C/5% CO~2~ in a humidified atmosphere.

-   DU145 cells are maintained in DMEM supplemented with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37˚C in 5% CO~2~ in a humidified atmosphere.

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  Transfect DU145, HCT116 WT, and HCT116 DICER^Ex5^ cells with siRNAsSeparate DU145 into five cultures each, and HCT116 WT, and HCT116 DICER^Ex5^ cells each into 4 different cultures.These will be biological replicates for each cell line.Seed cells 1.3 x 10^5^ cells per well of a 12-well plate for subsequent experiments:For measuring transfection efficiency (Step 1c ii):Seed 1 well (Cohort 1) per replicate per cell line.5 wells for DU145 cells4 wells for HCT116 WT cells4 wells for HCT116 Dicer^Ex5^ cellsFor cell proliferation assay (Step 2).Seed 4 wells (Cohorts 2-5) per replicate per cell line.20 wells for DU145 cells16 wells for HCT116 WT cells16 wells for HCT116 Dicer^Ex5^ cellsFor qPCR confirmation of siRNA knockdown (Step 3).Seed 4 wells (Cohorts 2-5) per replicate per cell line.20 wells for DU145 cells16 wells for HCT116 WT cells16 wells for HCT116 Dicer^Ex5^ cellsTransfect wells with 100 nM of appropriate siRNA using Dharmafect1 according to manufacturer's instructions.Note: make up a separate transfection mix for each biological replicate.Incubate wells for measuring transfection efficiency for 24-48 hr, then assess number of fluorescent cells transfected with siGLO to confirm \>90% transfection efficiency.If transfection is less than 90%, record efficiency for attempt, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.If modification to transfection is needed during first attempt(s), record and maintain modified steps for remaining replicates.Incubate wells for seeding the cell proliferation assay for 8 hr, then proceed to Step 2.Incubate wells for qPCR for 72 hr, then proceed to Step 3.

2.  Measure cell proliferationEight hours after transfection, trypsinize and resuspend cells. Split each well into 1 well each of four 12-well plates, seeding 20,000 cells/well. Incubate overnight.Two 12-well plates (a set) will provide sufficient wells to accommodate all replicates for one day of the time course per cell line.8 plates will be needed per cell line for a full 4 day time course.Starting on the following day (d0), fix one set of plates per cell line per day.Wash cells with PBS.Fix cells in 10% formalin solution for 10 min at room temperature.Store cells in PBS at 4°C until all plates are fixed.Plates should be collected on day 0, 1, 2 and 3.c. On day 3, stain all wells of all plates with crystal violet.Add 1 ml 0.1% Crystal Violet solution in 20% methanol.Shake gently for 15 min at room temperature.Wash 2 times in distilled water and let plates dry completely.Solubilize remaining crystal violet by adding 1 ml of 10% acetic acid to each well.Shake gently for 15 min at room temperature.Transfer 100 µl to a 96-well plate and measure OD at 595 nm in a plate reader.

3.  Confirm siRNA knock down with qPCR as in Protocol 1 Step 3. Perform qRT-PCR to measure mRNA expression for each siRNA transfection sample with its appropriate target and *ß-ACTIN*, and test each probe separately using RNA from the NC control transfection.PTEN*CNOT6LVAPAß-ACTIN* \[endogenous control communicated by original author\]Prepare 10 µl real-time PCR reaction in triplicate for each reaction consisting of:5 µl TaqMan mastermix0.5 µl TaqMan probe for the gene of interest4.5 µl cDNA (diluted 10x)Use standard TaqMan cycling protocol:50˚C 2 min95˚C 20 s40 cycles of 95˚C 1 s, 60˚C 20 s

### Deliverables {#s2-4-4}

-   Data to be collected:QC image data confirming transfection efficiency by measuring the number of fluorescent cells transfected with siGLOQC data for total RNA (A~260/280~ and A~260/230~ absorbance ratios)Raw qPCR data for each sample and a graph of the mean of each target gene normalized with *ß-ACTIN* and graphed relative to NC control.Raw numbers for optical density measures of colonies for each sample.

### Confirmatory analysis plan {#s2-4-5}

-   Statistical Analysis of the Replication Data:Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.Cell proliferation data: One-way ANOVA of AUC values of DU145 cells transfected with siRNA for *VAPA, CNOT6L, PTEN*, or siNC followed by Bonferroni-corrected planned comparisons:siNC vs each siRNA (3 comparisons total).Cell proliferation data: Two-way ANOVA of AUC values of HCT116^WT^ or HCT116 DICER^Ex5^ cells transfected with siRNA for *VAPA, CNOT6L, PTEN*, or siNC followed by Bonferroni-corrected planned comparisons:siNC vs. each siRNA, for each cell line (6 comparisons total).

-   Meta-analysis of original and replication attempt effect sizes:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

-   Additional exploratory analysis:siRNA knockdown confirmation \[additional control\]Two-way ANOVA of mRNA expression in HCT116 cells (wild type or DICER^Ex5^ cells) transfected with siRNA against NC, *VAPA, CNOT6L*, or *PTEN*, with the following Bonferroni-corrected comparisons:Non-coding siRNA vs. each of the ceRNA transfected cells (3 comparisons total).

### Known differences from the original study {#s2-4-6}

All known differences are listed in the materials and reagents section above, with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-4-7}

Extracted RNA integrity will be reported with A~260/280~ and A~260/230~ absorbance ratios, and transfection efficiency will be checked using the siGLO control. Cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/oblj1/>).

Protocol 5: Knock-down of ceRNA network genes results in AKT activation {#s2-5}
-----------------------------------------------------------------------

This experiment tests the effects of siRNA-mediated depletion of *PTEN, CNOT6L*, and *VAPA* expression on AKT activation in DU145, HCT116 WT, and HCT116 Dicer^Ex5^ cells. It replicates Figure 5A.

### Sampling {#s2-5-1}

-   This experiment will be repeated at least 7 times for a minimum power of 80%. The original Western blot data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.See Power Calculations section for details.

-   Each experiment consists of DU145, HCT116 WT, and HCT116 DICER^Ex5^ cells transfected with siRNA against *PTEN* ceRNAs:Cohort 1: siGLO RISC-free siRNA (siGLO)Cohort 2: siRNA against nontargeting control 2 (siNC)Cohort 3: siGENOME siRNA against *VAPA* (siVAPA)Cohort 4: siGENOME siRNA against *CNOT6L* (siCNO)Cohort 5: siGENOME siRNA against *PTEN* (siPTEN)

-   Effects of silencing ceRNAs will be tested withqRT-PCR to confirm target genes were silenced \[additional QC\]siGLO fluorescence cell counts to confirm transfection efficiencyAssessment of AKT phosphorylation by Western blot (Figure 5A)

### Materials and reagents {#s2-5-2}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                              Type                   Manufacturer                                                                      Catalog \#         Comments
  ------------------------------------ ---------------------- --------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------
  DU145 human prostate cancer cells    Cells                  ATCC                                                                              HTB-81             

  HCT116 WT and DICER^Ex5^ cells       Cells                  Horizon Discovery                                                                 HD R02-019         

  siGLO RISC-free siRNA siGLO          siRNA                  Dharmacon                                                                         D-001600-01-05     

  siGenome siRNA for\                  siRNA                  Dharmacon                                                                         D-001210-02-05     Catalog \# communicated\
  nontargeting control 2                                                                                                                                           by original authors

  siGenome siRNA for *VAPA*            siRNA                  Dharmacon                                                                         M-021382-01-0005   Catalog \# communicated\
                                                                                                                                                                   by original authors

  siGenome siRNA for *CNOT6L*          siRNA                  Dharmacon                                                                         M-016411-01-0005   Catalog \# communicated\
                                                                                                                                                                   by original authors

  siGenome siRNA for *PTEN*            siRNA                  Dharmacon                                                                         M-003023-02-0005   Catalog \# communicated\
                                                                                                                                                                   by original authors

  TaqMan probe *PTEN*                  qPCR probes            Life Technologies                                                                 Hs02621230_s1      

  TaqMan probe *CNOT6L*                qPCR probes            Life Technologies                                                                 Hs00375913_m1      

  TaqMan probe *VAPA*                  qPCR probes            Life Technologies                                                                 Hs00427749_m1      

  TaqMan control probe *ß-ACTIN*       qPCR probes            Life Technologies                                                                 Hs00969077_m1      Additional control

  TaqMan Fast Advanced Master Mix      qPCR reagent           Life Technologies                                                                 4444964            Communicated by original authors

  StepOne Plus Real-Time PCR system    Equipment              Applied Biosystems                                                                                   Replaces LightCycler 480 System

  Nanodrop 2000C Spectrometer          Equipment              Thermo Scientific                                                                                    

  Dulbecco\'s Modified Eagle\'s\       Cell Culture Reagent   Invitrogen                                                                        10313-039          Catalog \# communicated\
  Medium (DMEM)                                                                                                                                                    by original authors

  Fetal Bovine Serum (FBS)             Cell Culture Reagent   Invitrogen                                                                        10438-026          Catalog \# communicated\
                                                                                                                                                                   by original authors

  Penicillin/Streptomycin              Cell Culture Reagent   Life Technologies                                                                 15140-163          Communicated by\
                                                                                                                                                                   original authors

  Glutamine                            Cell Culture Reagent   Life Technologies                                                                 25030-081          Communicated by\
                                                                                                                                                                   original authors

  Trypsin                              Transfection Reagent   Life Technologies                                                                 15400-054          Communicated by\
                                                                                                                                                                   original authors

  Dharmafect 1                         Transfection Reagent   Thermo Fisher Scientific                                                          T200104            Communicated by\
                                                                                                                                                                   original authors

  PBS                                  Western Reagent        Life Technologies                                                                 14190250           Communicated by\
                                                                                                                                                                   original authors

  Lysis Buffer                         Western Reagent        RIPA lysis buffer: 50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.5%\                                 
                                                              sodium deoxycholate, 0.1% SDS, 5mM EDTA supplemented with proteinase inhibitors                      

  Protease inhibitors                  Western Reagent        Roche Diagnostics                                                                 11873580001        Communicated by\
                                                                                                                                                                   original authors

  Bradford Dye                         Western Reagent        Bio-Rad                                                                           500-0006           Catalog \# communicated by\
                                                                                                                                                                   original authors

  4--15% Mini-PROTEAN\                 Western Reagent        Biorad                                                                            456--1084          Replaces NuPage gels from Life Technologies (communicated by original authors)
  TGX Precast Protein Gels                                                                                                                                         

  Tris-Glycine SDS PAGE buffer (10x)   Western Reagent        National Diagnostic                                                               EC-870-4L          Replaces MOPS buffer from Invitrogen

  Nitrocellulose membranes             Western Reagent        Thermo Fisher Scientific                                                          45004006           Catalog \# communicated\
                                                                                                                                                                   by original authors

  10xTBS buffer                        Western Reagent        Biorad                                                                            170--6435          \
                                                                                                                                                                   Replaces NuPage buffer from Invitrogen

  Methanol                             Chemical               Pharmco                                                                           339000ACSCSGL      Communicated by\
                                                                                                                                                                   original authors

  Rabbit anti-pAKT (Ser473)\           Antibody               Cell Signaling                                                                    9271               Catalog \# communicated\
  polyclonal antibody (60kDa)                                                                                                                                      by original authors

  Rabbit anti-AKT polyclonal\          Antibody               Cell Signaling                                                                    9272               Catalog \# communicated\
  antibody (60kDa)                                                                                                                                                 by original authors

  Amersham ECL Western\                Western Blot Reagent   Amersham                                                                          RPN2108            Replaces ECL from Applied Biological Materials
  Blotting Detection Kit                                                                                                                                           

  Spectrophotometer                    Equipment              Beckman Coulter                                                                   Spectra max M2     Replaces Beckman Model DU-800 (communicated by original authors)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-5-3}

#### Notes: {#s39}

-   HCT116 cells (wild-type and mutant) are maintained in DMEM with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37°C/5% CO~2~ in a humidified atmosphere.

-   DU145 cells are maintained in DMEM supplemented with 10% FBS, ^\#^100 U/ml penicillin/100 µg/ml streptomycin, and ^\#^2 mM glutamine at 37˚C in 5% CO~2~ in a humidified atmosphere.

-   All cells will be sent for mycoplasma testing and STR profiling.

1.  Transfect DU145, HCT116 WT, and HCT116 DICER^Ex5^ cells with siRNAsSeed cells for subsequent experiments with 1.3 x 10^5^ cells per well in a 12-well plate:For measuring transfection efficiency (Step 1c ii):Seed 1 well (Cohort 1) per replicate.DU145 cellsHCT116 WT cellsHCT116 Dicer^Ex5^ cellsFor AKT activation and Western blot (Step 2).Seed 3 well (Cohort 2-5) per replicate.12 wells for DU145 cells12 wells for HCT116 WT cells12 wells for HCT116 Dicer^Ex5^ cellsTransfect wells with 100 nM of appropriate siRNA using Dharmafect1 according to manufacturer's instructions.Note: make up a separate transfection mix for each biological replicate.Incubate wells for measuring transfection efficiency for 24-48 hr, then assess number of fluorescent cells transfected with siGLO to confirm \>90% transfection efficiency.If transfection is less than 90%, record efficiency, exclude attempt and do not continue with the rest of the procedure. Repeat procedure until \>90% efficiency is obtained.If modification to transfection is needed, record and maintain modified steps for remaining replicates.

2.  Stimulate activation of AKT then measure levels of phosphorylated AKT by Western blot.After 72 hr, serum-starve cells overnight: replace media with serum-free media and incubate overnight (approximately 16 hr).The following morning, harvest one well at 0 min (pre-stimulation), re-stimulate the remaining cells by adding the appropriate volume of warmed 100% FBS to existing media in each trio of matched wells for a 10% final concentration. Incubate wells for 5 or 15 min.Harvest one well at 5 min and one well at 15 min post FBS addition.Harvest cells and perform Western blot as specified in Protocol 3 step 3.Note: load 10 µg of protein per well.Probe membranes specific primary antibodiespAKT (Ser473); 1:1000total AKT; 1:1000Loading controlNote from original author: Phosphorylated proteins are less stable in lysis buffer than non-phosphorylated proteins. Try to use fresh lysates for subsequent western blotting as far as possible. Transfer samples to the protein loading buffer as fast as possible and keep freeze thaw cycles to an absolute minimum.Normalize pAKT to total AKT for each sample.

3.  Repeat at least 6 additional times.

### Deliverables {#s2-5-4}

-   Data to be collected:QC image data confirming transfection efficiency by measuring the number of fluorescent cells transfected with siGLOQC data for total RNA (A~260/280~ and A~260/230~ absorbance ratios)Raw qPCR data for each sample and a graph of the mean of each target gene normalized with *ß-ACTIN* and graphed relative to NC control.Full scans of all films for each western including ladder.

### Confirmatory analysis plan {#s2-5-5}

-   Statistical Analysis of the Replication Data:Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.Two-way ANOVA of normalized pAKT levels of DU145 cells transfected with siRNA for *VAPA, CNOT6L, PTEN*, or siNC measured at 0 min, 5 min, and 15 min followed by Bonferroni-corrected planned contrasts:siNC vs each siRNA, collapsed across all times (3 contrasts total).Three-way ANOVA (3x4x2) of normalized pAKT levels of HCT116^WT^ or HCT116 DICER^Ex5^ cells transfected with siRNA for *VAPA, CNOT6L, PTEN*, or siNC measured at 0 min, 5 min, and 15 min:HCT116^WT^ cells with the following Bonferroni-corrected planned contrasts:siNC vs. each siRNA, collapsed across all times (3 contrasts total).HCT116 DICER^Ex5^ cells with the following Bonferroni-corrected planned contrasts:siNC vs. each siRNA, collapsed across all times (3 contrasts total).

-   Meta-analysis of original and replication attempt effect sizes:The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.

### Known differences from the original study {#s2-5-6}

All known differences are listed in the materials and reagents section above, with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.

### Provisions for quality control {#s2-5-7}

The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain \>90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded, and the procedure will be maintained for the remaining replicates. Images of Ponceau staining to confirm protein transfer. All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/oblj1/>).

### Power calculations {#s2-5-8}

For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:

<https://osf.io/c8hb5>

Protocol 1 {#s2-6}
----------

Summary of original luciferase activity data:

-   Note: data provided by original authors for Figure 3C

  siRNA    Luciferase activity   SD     N
  -------- --------------------- ------ ---
  siNC     100                   9.28   4
  siSER    70.29                 6.99   4
  siZNF    108.62                9.2    4
  siVAPA   47.54                 2.89   4
  siCNO    69.82                 3.69   4
  siPTEN   20.32                 1.11   4

### Test family {#s2-6-1}

-   2 tailed *t* test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.01

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  ----------------------------------------------------------------------------------
  Group 1   Group 2   Effect size *d*   A priori power   Group 1\      Group 2\
                                                         sample size   sample size
  --------- --------- ----------------- ---------------- ------------- -------------
  siNC      siSER     3.61647           81.9%            4             4

  siNC      siZNF     0.9329            80.2%^2^         30^2^         30^2^

  siNC      siVAPA    7.63300           98.5%^1^         3^1^          3^1^

  siNC      siCNO     4.27377           93.2%            4             4

  siNC      siPTEN    12.0568           99.9%^1^         3^1^          3^1^
  ----------------------------------------------------------------------------------

^1^ 4 samples per group will be used making the power \>99.9%.

^2^ A sensitivity calculation was performed since the original data showed a non-significant effect. The effect size that can be detected with 80% power and a sample size n=4 per group is 3.5378.

### Test family {#s2-6-2}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   ANOVA: Fixed effects, omnibus, one-way: alpha error = 0.05

### Power calculations {#s2-6-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2 ^performed with R software, version 3.1.2 ([@bib18]).

  Groups                   F test statistic   Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------ ------------------ -------------- ----------------- ---------------- -------------------
  siRNA silencing groups   F~(5,18)=~106.0    0.9672         5.4302            \>99.9%          12^1^

^1^ 24 total samples (4 per group) will be used based on the planned comparisons making the power \>99.9%.

### Test family {#s2-6-4}

-   Two-tailed *t* test, difference between two independent means, Bonferroni correction: alpha error = 0.01

### Power calculations {#s2-6-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  ------------------------------------------------------------------------------------------
  Group 1   Group 2   Effect size *d*   A priori power   Group 1\      Group 2 sample size
                                                         sample size   
  --------- --------- ----------------- ---------------- ------------- ---------------------
  siNC      siSER     3.61647           85.8%            4             4

  siNC      siZNF     0.9329            80.8%^2^         29^2^         29^2^

  siNC      siVAPA    7.63300           99.4%^1^         3^1^          3^1^

  siNC      siCNO     4.27377           95.4%            4             4

  siNC      siPTEN    12.0568           99.9%^1^         3^1^          3^1^
  ------------------------------------------------------------------------------------------

^1^ 4 samples per group will be used making the power \>99.9%.

^2^ A sensitivity calculation was performed since the original data showed a non-significant effect. The effect size that can be detected with 80% power and a sample size n=4 per group is 3.3711.

Summary of original qPCR gene expression data:

-   Note: data provided by original authors for Figure S3A

-   We estimated SD to be 0.001, when it was reported as zero.

  siRNA    mRNA expression   SD      Assumed N
  -------- ----------------- ------- -----------
  siSER    0.03              0.001   4
  siZNF    0.35              0.11    4
  siVAPA   0.03              0.001   4
  siCNO    0.07              0.01    4
  siPTEN   0.1               0.04    4

### Test family {#s2-6-6}

-   2 tailed *t* test, Wilcoxon-Signed Ranks one-sample test, Bonferroni's correction: alpha error = 0.01

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group    Effect size *d*   A priori power   Sample size
  -------- ----------------- ---------------- -------------
  siSER    970.00            99.9%            3
  siZNF    5.91              97.7%            4
  siVAPA   970.00            99.9%            3
  siCNO    93.00             99.9%            3
  siPTEN   22.50             99.9%            3

### Test family {#s2-6-7}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   Two-tailed *t* test, difference from a constant, Bonferroni correction: alpha error = 0.01

### Power calculations {#s2-6-8}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group    Effect size *d*   A priori power   sample size
  -------- ----------------- ---------------- -------------
  siSER    970.00            99.9%            3
  siZNF    5.91              99.0%            4
  siVAPA   970.00            99.9%            3
  siCNO    93.00             99.9%            3
  siPTEN   22.50             99.9%            3

Protocol 2 {#s2-7}
----------

Summary of original Luciferase data:

-   Note: data provided by original authors for Figure 3D.

  siRNA          Luciferase Activity   SD      N
  -------------- --------------------- ------- ---
  Empty Vector   100                   8.83    4
  SER 3\'U       127.86                11.59   4
  VAPA 3\'U1     140.84                17.8    4
  VAPA 3\'U2     150.25                9.37    4
  CNO 3\'U1      142.91                9.92    4
  CNO 3\'U2      145.88                10.59   4
  PTEN 3\'U      153.32                2.06    4

### Test family {#s2-7-1}

-   2 tailed *t* test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.00833

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group 1        Group 2      Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  -------------- ------------ ----------------- ---------------- --------------------- ---------------------
  Empty Vector   SER 3\'U     2.70411           85.7%            6                     6
  Empty Vector   VAPA 3\'U1   2.90675           91.0%            6                     6
  Empty Vector   VAPA 3\'U2   5.51955           81.3%^1^         3^1^                  3^1^
  Empty Vector   CNO 3\'U1    4.56935           94.6%^1^         4^1^                  4^1^
  Empty Vector   CNO 3\'U2    4.70574           95.7%^1^         4^1^                  4^1^
  Empty Vector   PTEN 3\'U    8.31642           99.0%^1^         3^1^                  3^1^

^1^ 6 samples per group will be used making the power \>99.9%.

### Test family {#s2-7-2}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   ANOVA: Fixed effects, omnibus, one-way: alpha error = 0.05

### Power calculations {#s2-7-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.1.2 ([@bib18]).

  Groups               F test statistic     Partial η^2^   Effect size *f*   A priori power   Total sample size
  -------------------- -------------------- -------------- ----------------- ---------------- -------------------
  PTEN ceRNAs 3'UTRs   F~(6,\ 21)=~11.347   0.7643         5.4302            99.9%            14^1^

^1^ 42 total samples (6 per group) will be used based on the planned comparisons making the power \>99.9%.

### Test family {#s2-7-4}

-   Two-tailed *t* test, difference between two independent means, Bonferroni correction: alpha error = 0.00833

### Power calculations {#s2-7-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group 1        Group 2      Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  -------------- ------------ ----------------- ---------------- --------------------- ---------------------
  Empty Vector   SER 3\'U     2.70411           88.5%            6                     6
  Empty Vector   VAPA 3\'U1   2.90675           82.4%^1^         5^1^                  5^1^
  Empty Vector   VAPA 3\'U2   5.51955           86.9%^2^         3^2^                  3^2^
  Empty Vector   CNO 3\'U1    4.56935           96.5%^2^         4^2^                  4^2^
  Empty Vector   CNO 3\'U2    4.70574           97.4%^2^         4^2^                  4^2^
  Empty Vector   PTEN 3\'U    8.31642           99.6%^2^         3^2^                  3^2^

^1^ 6 samples per group will be used making the power 96.2%.

^2^ 6 samples per group will be used making the power 99.9%.

Protocol 3 {#s2-8}
----------

Summary of original Western blot data:

-   Note: data provided by original authors for Figure 3H.

  siRNA      Cell type   PTEN expression   SD    N
  ---------- ----------- ----------------- ----- ---
  siNC       WT          100               8.3   4
  DicerEx5   100         4.8               4     
  siSER      WT          52.6              8.9   4
  DicerEx5   117         6.5               4     
  SiVAPA     WT          51.7              6.5   4
  DicerEx5   107.5       9.4               4     
  siCNO      WT          58.7              4.5   4
  DicerEx5   113         4.4               4     
  siPTEN     WT          1.9               0.2   4
  DicerEx5   1.3         0.001             4     

### Test family {#s2-8-1}

-   2 tailed *t* test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.00625

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  ----------------------------------------------------------------------------------------------------------------------
  Group 1                    Group 2                      Effect size *d*   A priori power   Group 1\      Group 2\
                                                                                             sample size   sample size
  -------------------------- ---------------------------- ----------------- ---------------- ------------- -------------
  WT siNC                    WT siSER                     5.50828           98.4%            4             4

  WT siNC                    WT siVAPA                    6.47928           87.2%^1^         3^1^          3^1^

  WT siNC                    WT siCNO                     6.18627           83.9%^1^         3^1^          3^1^

  WT siNC                    WT siPTEN                    16.71013          99.9%^1^         3^1^          3^1^

  Sensitivity Calculations   Detectable Effect size *d*   A priori power    Group 1\         Group 2\      
                                                                            sample size      sample size   

  Dicer siNC                 Dicer siSER                  3.895             80%              4             4

  Dicer siNC                 Dicer siVAPA                 3.895             80%              4             4

  Dicer siNC                 Dicer siCNO                  3.895             80%              4             4

  Dicer siNC                 Dicer siPTEN                 3.895             80%              4             4
  ----------------------------------------------------------------------------------------------------------------------

^1^ 4 samples per group will be used making the power \>99%.

### Test family {#s2-8-2}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   Two-way ANOVA: Fixed effects, main effects, special and interactions: alpha error = 0.05

### Power calculations {#s2-8-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.1.2 ([@bib17]; [@bib18]).

  --------------------------------------------------------------------------------------------------------------------
  Groups                    F test statistic     Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------- -------------------- -------------- ----------------- ---------------- -------------------
  siRNA silencing groups\   F~(4,30)~= 54.237\   0.87852        2.6892            89.9%^1^         14^1^
  in WT or DicerEx5 cells   (interaction)                                                          

  --------------------------------------------------------------------------------------------------------------------

^1^ 40 total samples (4 per group) will be used based on the planned comparisons making the power \>99.9%.

### Test family {#s2-8-4}

-   Two-tailed *t* test, difference between two independent means, Bonferroni correction: alpha error = 0.00625

### Power calculations {#s2-8-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  ----------------------------------------------------------------------------------------------------------------------
  Group 1                    Group 2                      Effect size *d*   A priori power   Group 1\      Group 2\
                                                                                             sample size   sample size
  -------------------------- ---------------------------- ----------------- ---------------- ------------- -------------
  WT siNC                    WT siSER                     5.50828           81.1%            3^1^          3^1^

  WT siNC                    WT siVAPA                    6.47928           92.0%            3^1^          3^1^

  WT siNC                    WT siCNO                     6.18627           89.5%            3^1^          3^1^

  WT siNC                    WT siPTEN                    16.71013          82.6%^1^         2^1^          2^1^

  Sensitivity Calculations   Detectable Effect size *d*   A priori power    Group 1\         Group 2\      
                                                                            sample size      sample size   

  Dicer siNC                 Dicer siSER                  3.697             80%              4             4

  Dicer siNC                 Dicer siVAPA                 3.697             80%              4             4

  Dicer siNC                 Dicer siCNO                  3.697             80%              4             4

  Dicer siNC                 Dicer siPTEN                 3.697             80%              4             4
  ----------------------------------------------------------------------------------------------------------------------

^1^ 4 samples per group will be used making the power \>99.9%.

Summary of original mRNA expression data:

-   Note: data provided by original authors for Figure S3B.

  siRNA      Cell Type   mRNA expression   SD       N
  ---------- ----------- ----------------- -------- ---
  siSER      WT          0.036             0.0049   4
  DicerEx5   0.028       0.0007            4        
  SiVAPA     WT          0.027             0.0019   4
  DicerEx5   0.034       0.0005            4        
  siCNO      WT          0.107             0.033    4
  DicerEx5   0.033       0.0025            4        
  siPTEN     WT          0.075             0.0237   4
  DicerEx5   0.115       0.0414            4        

### Test family {#s2-8-6}

-   2 tailed *t* test, Wilcoxon-Signed Ranks one-sample test, Bonferroni's correction: alpha error = 0.00625

### Power calculations {#s2-8-7}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group          Effect size *d*   A priori power   Group 1 sample size
  -------------- ----------------- ---------------- ---------------------
  WT siSER       196.75            99.5%            3
  WT siVAPA      512.00            99.5%            3
  WT siCNO       27.06             99.5%            3
  WT siPTEN      39.03             99.5%            3
  Dicer siSER    1388.50           99.5%            3
  Dicer siVAPA   1932.00           99.5%            3
  Dicer siCNO    386.80            99.5%            3
  Dicer siPTEN   21.38             99.5%            3

### Test family {#s2-8-8}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   Two-tailed *t* test, difference from a constant (mu=1), Bonferroni correction: alpha error = 0.00625

### Power calculations {#s2-8-9}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group          Effect size *d*   A priori power   Group 1 sample size
  -------------- ----------------- ---------------- ---------------------
  WT siSER       196.75            99.9%            3
  WT siVAPA      512.00            99.9%            3
  WT siCNO       27.06             99.9%            3
  WT siPTEN      39.03             99.9%            3
  Dicer siSER    1388.50           99.9%            3
  Dicer siVAPA   1932.00           99.9%            3
  Dicer siCNO    386.80            99.9%            3
  Dicer siPTEN   21.38             99.9%            3

Protocol 4 {#s2-9}
----------

Summary of original cell proliferation data:

-   Note: data of mean values provided by original authors for Figure 5B.

                             Cell Proliferation (Optical Density)                   
  ------------------ ------- -------------------------------------- ------- ------- -------
  Cell Type          siRNA   Day 0                                  Day 1   Day 2   Day 3
  DU145              siNC    0                                      0.08    0.37    0.92
  siPTEN             0       0.16                                   0.83    1.96    
  siCNO              0       0.06                                   0.63    1.66    
  siVAPA             0       0.12                                   0.78    1.75    
  HCT116 WT          siNC    0                                      0.30    0.91    1.35
  siPTEN             0       0.60                                   1.63    2.07    
  siCNO              0       0.77                                   1.98    2.19    
  siVAPA             0       0.66                                   1.65    1.98    
  HCT116 Dicer Ex5   siNC    0                                      0.12    0.49    0.74
  siPTEN             0       0.69                                   1.72    1.90    
  siCNO              0       0.49                                   1.09    1.75    
  siVAPA             0       0.30                                   0.95    1.34    

-   Area under the curve calculation with R software, version 3.1.2 ([@bib18]).

  Cell Type          siRNA   Area under the curve   SD      N
  ------------------ ------- ---------------------- ------- ---
  DU145              siNC    0.910                  0.235   3
  siPTEN             1.970   0.140                  3       
  siCNO              1.520   0.141                  3       
  siVAPA             1.775   0.076                  3       
  HCT116 WT          siNC    1.885                  0.180   3
  siPTEN             3.265   0.156                  3       
  siCNO              3.845   0.290                  3       
  siVAPA             3.300   0.275                  3       
  HCT116 Dicer Ex5   siNC    0.980                  0.012   3
  siPTEN             3.360   0.310                  3       
  siCNO              2.455   0.145                  3       
  siVAPA             1.920   0.285                  3       

DU145 cells {#s2-10}
-----------

### Test family {#s2-10-1}

-   2 tailed, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.0167

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  Group 1   Group 2   Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  --------- --------- ----------------- ---------------- --------------------- ---------------------
  siNC      siPTEN    5.115             89.5%            3                     3
  siNC      siCNO     2.944             89.4%            5                     5
  siNC      siVAPA    4.174             96.3%            4                     4

### Test family {#s2-10-2}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   One way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05

### Power calculations {#s2-10-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2 ^performed with R software, version 3.1.2 ([@bib18]).

  ----------------------------------------------------------------------------------------------------------------------
  Groups                            F test statistic   Partial η2   Effect size f   A priori power   Total sample size
  --------------------------------- ------------------ ------------ --------------- ---------------- -------------------
  Optical density of DU145 cells\   F(6, 24) =14.26    0.7810       1.8884          82.73%           16^1^
  transfected with siRNAs                                                                            

  ----------------------------------------------------------------------------------------------------------------------

^1^60 total samples (5 per group) will be used based on the planned comparisons making the power \>99.99%.

### Test family {#s2-10-4}

-   Two-tailed *t* test, difference between two independent means, Bonferroni correction: alpha error = 0.0167

### Power calculations {#s2-10-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Cells   Group 1   Group 2   Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  ------- --------- --------- ----------------- ---------------- --------------------- ---------------------
  DU145   siNC      siPTEN    5.115             92.9%^1^         3^1^                  3^1^
  siNC    siCNO     2.944     91.7%             5                5                     
  siNC    siVAPA    4.174     97.6%^1^          4^1^             4^1^                  

^1^5 samples per group will be used making the power \>99%.

HCT116 cells {#s2-11}
------------

### Test family {#s2-11-1}

-   2 tailed, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.00833

Power Calculations performed with G\*Power software, version 3.1.7 ([@bib10]).

  Cells              Group 1   Group 2   Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size
  ------------------ --------- --------- ----------------- ---------------- --------------------- ---------------------
  HCT116 WT          siNC      siPTEN    6.695             93.4%            3                     3
  siNC               siCNO     3.853     84.1%             4                4                     
  siNC               siVAPA    5.463     80.5%             3                3                     
  HCT116 Dicer Ex5   siNC      siPTEN    10.452            99.9%            3                     3
  siNC               siCNO     6.478     91.8%             3                3                     
  siNC               siVAPA    4.128     89.1%             4                4                     

### Test family {#s2-11-2}

-   Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.

-   Two way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05

### Power calculations {#s2-11-3}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.1.2 ([@bib18]).

  --------------------------------------------------------------------------------------------------------------------
  Groups                          F test statistic   Partial η2   Effect size f   A priori power   Total sample size
  ------------------------------- ------------------ ------------ --------------- ---------------- -------------------
  Optical density of\             F(3, 23) =14.08    0.7253       1.6249          81.69%           12^1^
  HCT116 WT, and DICEREx5\                                                                         
  cells transfected with siRNAs                                                                    

  --------------------------------------------------------------------------------------------------------------------

^1^24 total samples (3 per group) will be used based on the planned comparisons making the power \>99.99%.

### Test family {#s2-11-4}

-   Two-tailed *t* test, difference between two independent means, Bonferroni correction: alpha error = 0.00833

### Power calculations {#s2-11-5}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  Cells                      Group 1                      Group 2          Effect size *d*       A priori power        Group 1 sample size   Group 2 sample size
  -------------------------- ---------------------------- ---------------- --------------------- --------------------- --------------------- ---------------------
  HCT116 WT                  siNC                         siPTEN           6.695                 96.3%                 3                     3
  siNC                       siCNO                        3.853            87.9%                 3                     3                     
  siNC                       siVAPA                       5.463            86.2%                 3                     3                     
  Sensitivity Calculations   Detectable Effect size *d*   A priori power   Group 1 sample size   Group 2 sample size                         
  HCT116 Dicer Ex5           siNC                         siPTEN           3.495                 80%                   4                     4
  siNC                       siCNO                        3.495            80%                   4                     4                     
  siNC                       siVAPA                       3.495            80%                   4                     4                     

Protocol 5 {#s2-12}
----------

Summary of original AKT Activation data

-   Note: data provided by original authors for Figure 5A.We used the average band intensity for siNC since they were measured twice.

                             pAkt/Total Akt           
  ------------------ ------- ---------------- ------- --------
  Cell Type          siRNA   0 min            5 min   15 min
  DU145              siNC    1                3.2     1.95
  siPTEN             5       8.1              6.9     
  siCNO              0.8     4.1              3.4     
  siVAPA             2.1     10.9             6.6     
  HCT116 WT          siNC    1                2.35    2.45
  siPTEN             6.3     9.5              9.5     
  siCNO              1.2     4.1              3       
  siVAPA             1.8     4.4              3.5     
  HCT116 Dicer Ex5   siNC    1                5.15    2.25
  siPTEN             5.3     14.7             7.2     
  siCNO              0.7     4.8              0.8     
  siVAPA             0.8     7                3.1     

DU145 cells {#s2-13}
-----------

Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

### Test family {#s2-13-1}

-   2-Way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05 for DU145 cells

### Power calculations {#s2-13-2}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.1.2 ([@bib18]).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Groups                          Variance estimate   F test statistic F(3,24) (siRNA main effect)   Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------------- ------------------- ---------------------------------------------- -------------- ----------------- ---------------- -------------------
  Akt activation in DU145\        2%                  4598.79                                        0.9983         23.973            99.9%            13
  Cells transfected with\                                                                                                                              
  siRNAs after 0, 5, and 15 min                                                                                                                        

  15%                             81.756              0.9109                                         3.1968         91.4%             14               

  28%                             23.463              0.7457                                         1.7126         80.4%             15               

  40%                             11.497              0.5897                                         1.1988         87.2%             18               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Test family {#s2-13-3}

-   ANOVA F test statistic and planned contrasts with Bonferroni correction: alpha error = 0.01667

### Power calculations {#s2-13-4}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  ------------------------------------------------------------------------------------------
  Cells   Group 1\      Group 2\      Estimated\   Effect size *f*   A priori\   Samples\
          across time   across time   variance                       power       per group
  ------- ------------- ------------- ------------ ----------------- ----------- -----------
  DU145   siNC          siPTEN        2%           18.533            92.0%       2

  15%     2.4710        98.6%         2                                          

  28%     1.3238        82.6%         2                                          

  40%     0.9266        83.7%         2                                          

  siNC    siCNO         2%            2.8770       85.5%             2           

  15%     0.3836        80.3%         7                                          

  28%     0.2055        80.0%         21                                         

  40%     0.1438        80.0%         43                                         

  siNC    siVAPA        2%            17.997       91.1%             2           

  15%     2.400         98.1%         2                                          

  28%     1.2855        80.3%         2                                          

  40%     0.8999        81.2%         2                                          
  ------------------------------------------------------------------------------------------

HCT 116 cells {#s2-14}
-------------

Note: The original data do not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

### Test family {#s2-14-1}

-   3-Way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.025 for HCT116^WT^ and HCT116^DicerEx5^ cells comparing AKT activation over time.

### Power calculations {#s2-14-2}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

-   ANOVA F test statistic and partial η^2^performed with R software, version 3.1.2 ([@bib18]).For a given relative variance, 10,000 simulations were run and the F statistic and partial η^2^ was calculated for each simulated data set.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Groups                          Variance Estimate   F test statistic F(3,48) (cell line, siRNA interaction)   Partial η^2^   Effect size *f*   A priori power   Total sample size
  ------------------------------- ------------------- --------------------------------------------------------- -------------- ----------------- ---------------- -------------------
  Akt activation in HCT116^WT^\   2%                  201.70                                                    0.9173         3.3310            99.3%            26
  or HCT116^DicerEx5^ cells\                                                                                                                                      
  transfected with siRNAs\                                                                                                                                        
  after 0, 5 and 15 min                                                                                                                                           

  15%                             4.7410              0.2162                                                    0.5251         80.1%             47               

  28%                             2.1892              0.1128                                                    0.3566         80.1%             91               

  40%                             1.6636              0.0878                                                    0.3103         80.4%             119              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Test family {#s2-14-3}

-   ANOVA F test statistic and planned contrasts with Bonferroni correction: alpha error = 0.01667 for each group of comparisons (cell type).

### Power calculations {#s2-14-4}

-   Performed with G\*Power software, version 3.1.7 ([@bib10]).

  -------------------------------------------------------------------------------------------
  Cells        Group 1\      Group 2\               Effect size *f*   A priori\   Samples\
               across time   across time                              power       per group
  ------------ ------------- ------------- -------- ----------------- ----------- -----------
  HCT116^WT^   siNC          siPTEN        2%       18.322            99.9%       2

  15%          2.4429        99.9%         2                                      

  28%          1.3087        99.9%         2                                      

  40%          0.9161        99.9%         2                                      

  siNC         siCNO         2%            2.3489   99.9%             2           

  15%          0.3132        83.8%         5                                      

  28%          0.1678        81.1%         16                                     

  40%          0.1174        80.4%         32                                     

  siNC         siVAPA        2%            3.6643   99.9%             2           

  15%          0.4886        94.8%         3                                      

  28%          0.2617        83.3%         7                                      

  40%          0.1832        82.9%         14                                     
  -------------------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------------------------------------------------------
  Cells                     Group 1\                   Group 2\                             Effect size *f*   A priori\   Samples\
                            across time                across time                                            power       per group
  ------------------------- -------------------------- ---------------- ------------------- ----------------- ----------- -----------
  HCT116^DicerEx5^          siNC                       siPTEN           2%                  17.664            99.9        2

  15%                       2.3552                     99.9             2                                                 

  28%                       1.2617                     99.9%            2                                                 

  40%                       0.8832                     99.9%            2                                                 

  Sensitivity calculation   Detectable effect size f   A priori power   Samples per group                                 

  siNC                      siCNO                      2%               0.4971              80.0%             2           

  15%                       0.2999                     80.0%            5                                                 

  28%                       0.1742                     80.0%            16                                                

  40%                       0.1170                     80.0%            32                                                

  Sensitivity calculation   Detectable effect size f   A priori power   Samples per group                                 

  siNC                      siVAPA                     2%               0.4971              80.0%             2           

  15%                       0.2999                     80.0%            5                                                 

  28%                       0.1742                     80.0%            16                                                

  40%                       0.1170                     80.0%            32                                                
  -----------------------------------------------------------------------------------------------------------------------------------

In order to produce quantitative replication data, we will run the experiment seven times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tony Hunter as the Senior Editor. One of the four reviewers, Klaus Rajewsky (Reviewer 4), has agreed to reveal his identity.

Your Registered report has been reviewed by four expert referees. As you will see, all are quite positive about the proposed work. Please address the very minor points raised by the reviewers before uploading your final files but consider the Report to be In Press.

Reviewer \#1:

This Registered report describes the proposed replication plan of key experiments from \"Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs\" by Tay and colleagues, published in Cell in 2011 (Tay et al., 2011).

For all protocols, the authors propose use ANOVA to analyze the data. Please check for outliers and make sure that the data do not violate the assumptions of the ANOVA: normality and homoscedasticity. If the data do not fit the assumptions well enough, try to find a data transformation that makes them fit. If this doesn\'t work, suggest/apply a nonparametric counterpart of ANOVA.

Reviewer \#2:

The authors of this report propose to replicate experiments within Coding-independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs, by Tay et al., 2011. This study reported a set of genes (NCOA7, BCL11B, SERINC1, ZNF460, NUDT13, DTWD2, and VAPA) regulating the expression of the tumor suppressor PTEN by acting as competing endogenous RNAs (ceRNAs). The authors describe the following as the essential results of Tay et al., 2011: 1.) When DU145 cells are transfected with a luciferase construct containing the PTEN 3′UTR and siRNAs against each of the putative ceRNAs, luciferase activity decreases in comparison to transfections with the construct and a control siRNA. 2.) When the same cells are transfected with a luciferase construct containing the PTEN 3′UTR and a construct containing the 3′UTR of one of the ceRNAs, luciferase activity increases in comparison to when transfected with the construct and a control construct. 3.) When HCT WT cells are transfected with siRNAs against each of the identified ceRNAs, PTEN expression as measured by protein blot decreases in comparison to transfections with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, which is impaired in production of miRNA levels, the reduction of PTEN upon ceRNA knockdown is abrogated, supporting the idea that the response to modulating the ceRNAs is miRNA dependent. 4.) When DU125 and HCT WT cells are transected with an siRNA against PTEN or one of two ceRNAs (CNO a VAPA), cell proliferation increases in comparison to when transfected with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, the increased proliferation upon knockdown of either of the two ceRNAs, but not PTEN, is reduced. 5.) When DU125 and HCT WT cells are transected with an siRNA against PTEN or one of two ceRNAs (CNO a VAPA) and serum starved, phosphorylation of Akt increases after restimulation, in comparison to when transfected with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, the increase in Akt phosphorylation upon knockdown of either of the two ceRNAs, but not PTEN, is abrogated.

Considered questions:

1\) Do the experiments chosen embody the main conclusions drawn from the original article?

These experiments embody the main conclusions. Protocols 1 and 2 are designed to demonstrate that each ceRNA positively regulates PTEN protein levels through the 3′ UTR of both the ceRNA and PTEN transcript. Protocol 3 is designed to demonstrate that this effect is dependent on miRNAs. Protocol 4 is designed to demonstrate that loss of PTEN or its ceRNAs increases cell proliferation, and Protocol 5 is designed to demonstrate that loss of PTEN or its ceRNAs increases Akt phosphorylation, which is a proliferation signal.

2\) Do the authors accurately summarize the literature, especially with respect to other direct replications?

Yes.

3\) Are the proposed experiments appropriately designed?

The original experiments corresponding to each of the five protocols had only a single siRNA or UTR control. If the authors had the latitude to add more controls, the results would be more robust, although this would go beyond the scope of simply repeating the published experiments. In Protocol 3 and 5 the protein blots could be performed loading a dilution series of total protein (e.g., 5 µg, 2 µg, 1 µg) from the control sample, to ensure that quantitation is in the linear range and not confounded by overexposure (a concern of the original authors).

3\) Are the proposed statistical analyses rigorous and appropriate?

Yes.

4\) What can the replication team do to maximize the quality of the replication?

The team has done a thorough job in designing this attempted replication.

Reviewer \#3:

The authors present a clear, well-controlled plan for this replication study. They have also included comments and experimental details provided by the original authors. They should address the minor comments listed below before this manuscript can be accepted for publication.

Comments for the authors:

Paragraph one, Introduction -- cognante should be cognate.

Paragraph three, Introduction -- CNOTL6 should be CNOT6L.

Paragraph eight, Introduction -- The Poliseno group should be The Pandolfi group.

Protocol 1, "Materials and Reagents" table (and all other mentions of the TaqMan probes) -- The original product numbers are specified in the extreme left column. For example, the PTEN TaqMan probe used is Hs02621230_s1.

Protocol 5, "Materials and Reagents" table -- The P-Akt antibody should be 9271 (Cell signalling). This is for P-Akt Ser473, which is what was examined in the original paper. Cat number 9275 is for the P-Akt Thr308 antibody.

Reviewer \#4:

We have carefully checked the proposal with respect to the 5 criteria specified in the reviewers\' guidelines and found the proposal just perfect. Of course nowadays one would like to see the Pandolfi experiments controlled by CRISPR/Cas mutagenesis, but this is apparently not part of the present replication program.

10.7554/eLife.12470.003

Author response

Reviewer \#1:

For all protocols, the authors propose use ANOVA to analyze the data. Please check for outliers and make sure that the data do not violate the assumptions of the ANOVA: normality and homoscedasticity. If the data do not fit the assumptions well enough, try to find a data transformation that makes them fit. If this doesn\'t work, suggest/apply a nonparametric counterpart of ANOVA.

We appreciate the point that the reviewer has brought up. We have added the following statement to the analysis sections where appropriate.

"Note: At the time of analysis we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test."

Reviewer \#2:

The authors of this report propose to replicate experiments within Coding-independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs, by Tay et al., 2011. This study reported a set of genes (NCOA7, BCL11B, SERINC1, ZNF460, NUDT13, DTWD2, and VAPA) regulating the expression of the tumor suppressor PTEN by acting as competing endogenous RNAs (ceRNAs). The authors describe the following as the essential results of Tay et al., 2011: 1.) When DU145 cells are transfected with a luciferase construct containing the PTEN 3′UTR and siRNAs against each of the putative ceRNAs, luciferase activity decreases in comparison to transfections with the construct and a control siRNA. 2.) When the same cells are transfected with a luciferase construct containing the PTEN 3′UTR and a construct containing the 3′UTR of one of the ceRNAs, luciferase activity increases in comparison to when transfected with the construct and a control construct. 3.) When HCT WT cells are transfected with siRNAs against each of the identified ceRNAs, PTEN expression as measured by protein blot decreases in comparison to transfections with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, which is impaired in production of miRNA levels, the reduction of PTEN upon ceRNA knockdown is abrogated, supporting the idea that the response to modulating the ceRNAs is miRNA dependent. 4.) When DU125 and HCT WT cells are transected with an siRNA against PTEN or one of two ceRNAs (CNO a VAPA), cell proliferation increases in comparison to when transfected with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, the increased proliferation upon knockdown of either of the two ceRNAs, but not PTEN, is reduced. 5.) When DU125 and HCT WT cells are transected with an siRNA against PTEN or one of two ceRNAs (CNO a VAPA) and serum starved, phosphorylation of Akt increases after restimulation, in comparison to when transfected with a control siRNA. When this experiment is repeated in HCT Dicer^Ex5^, the increase in Akt phosphorylation upon knockdown of either of the two ceRNAs, but not PTEN, is abrogated.

Considered questions:

1\) Do the experiments chosen embody the main conclusions drawn from the original article?These experiments embody the main conclusions. Protocols 1 and 2 are designed to demonstrate that each ceRNA positively regulates PTEN protein levels through the 3′ UTR of both the ceRNA and PTEN transcript. Protocol 3 is designed to demonstrate that this effect is dependent on miRNAs. Protocol 4 is designed to demonstrate that loss of PTEN or its ceRNAs increases cell proliferation, and Protocol 5 is designed to demonstrate that loss of PTEN or its ceRNAs increases Akt phosphorylation, which is a proliferation signal.2) Do the authors accurately summarize the literature, especially with respect to other direct replications?Yes.

3\) Are the proposed experiments appropriately designed?The original experiments corresponding to each of the five protocols had only a single siRNA or UTR control. If the authors had the latitude to add more controls, the results would be more robust, although this would go beyond the scope of simply repeating the published experiments. In Protocol 3 and 5 the protein blots could be performed loading a dilution series of total protein (e.g., 5 µg, 2 µg, 1 µg) from the control sample, to ensure that quantitation is in the linear range and not confounded by overexposure (a concern of the original authors).

We agree with the reviewer that there can be much performed outside of what would be considered a direct replication and that these questions should be answered outside of this experimental setup. As for the Western blotting protocols, multiple exposures will be taken at various times to minimize the risk of overexposure with all images made publically available.

Reviewer \#3:Paragraph one, Introduction -- cognante should be cognate

This has been corrected in the revised manuscript.

Paragraph three, Introduction -- CNOTL6 should be CNOT6L

This has been corrected in the revised manuscript.

Paragraph eight, Introduction -- The Poliseno group should be The Pandolfi group

This has been corrected in the revised manuscript.

Protocol 1, "Materials and Reagents" table (and all other mentions of the TaqMan probes) -- The original product numbers are specified in the extreme left column. For example, the PTEN TaqMan probe used is Hs02621230_s1.

We have moved the product numbers for each TaqMan probe to the appropriate fourth column and removed the comment that the original product number was not specified.

Protocol 5, "Materials and Reagents" table -- The P-Akt antibody should be 9271 (Cell signalling). This is for P-Akt Ser473, which is what was examined in the original paper. Cat number 9275 is for the P-Akt Thr308 antibody.

Thank you for this comment. We confirmed with the original authors that the catalog number 9271 (for the P-Akt Ser473) should be used and have corrected this in the revised manuscript.

Reviewer \#4:We have carefully checked the proposal with respect to the 5 criteria specified in the reviewers\' guidelines and found the proposal just perfect. Of course nowadays one would like to see the Pandolfi experiments controlled by CRISPR/Cas mutagenesis, but this is apparently not part of the present replication program.

We appreciate the reviewers' note and agree that such exploratory analyses would be appropriate for future replication attempts.
